Literature DB >> 9430697

Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells.

D Bandyopadhyay1, M Mandal, L Adam, J Mendelsohn, R Kumar.   

Abstract

Binding of extracellular ligands to epidermal growth factor receptors (EGFR) activate signal transduction pathways associated with cell proliferation, and these events are inhibited by monoclonal antibodies against EGFR. Since efficient DNA repair in actively growing cells may require growth factor signaling, it was of interest to explore any linkage between EGFR-mediated signaling and DNA-dependent protein kinase (DNA-PK), an enzyme believed to be involved in repairing double strand breaks and V(D)J recombination. We report that anti-EGFR monoclonal antibodies (mAbs), and not EGFR ligands, trigger a specific early physical interaction between EGFR and a 350-kDa catalytic subunit of DNA or its regulatory heterodimeric complex Ku70/80, in a variety of cell types, both in vivo and in vitro. Inhibition of EGFR signaling by anti-EGFR mAb was accompanied by a reduction in the levels of the DNA-PK and its activity in the nuclear fraction. Confocal imaging revealed that a substantial amount of DNA-PK was co-localized with EGFR in anti-EGFR mAb-treated cells. Anti-EGFR mAb-induced physical interaction between EGFR and DNA-PK or Ku70/80 was dependent on the presence of EGFR, but not on the levels of EGFR. The EGFR associated with DNA-PK or Ku70/80 retains its intrinsic kinase activity. Our findings demonstrate the existence of a novel cellular pathway in mammalian cells that involves physical interactions between EGFR and DNA-PK or Ku70/80 in response to inhibition of EGFR signaling. Our present observations suggest a possible role of EGFR signaling in maintenance of the nuclear levels of DNA-PK, and interference in EGFR signaling may possibly result in the impairment of DNA repair activity in the nuclei in anti-EGFR mAb-treated cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9430697     DOI: 10.1074/jbc.273.3.1568

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

2.  Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death.

Authors:  C R Yang; K Leskov; K Hosley-Eberlein; T Criswell; J J Pink; T J Kinsella; D A Boothman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Authors:  Gianmaria Liccardi; John A Hartley; Daniel Hochhauser
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

4.  Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes.

Authors:  Yi-Chun Chen; E Scott Colvin; Katherine E Griffin; Bernhard F Maier; Patrick T Fueger
Journal:  Diabetologia       Date:  2014-07-04       Impact factor: 10.122

Review 5.  NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling.

Authors:  Ralph A Bradshaw; Jay Pundavela; Jordane Biarc; Robert J Chalkley; A L Burlingame; Hubert Hondermarck
Journal:  Adv Biol Regul       Date:  2014-11-20

6.  Nuclear EGFR is required for cisplatin resistance and DNA repair.

Authors:  Sheng-Chieh Hsu; Stephanie A Miller; Yan Wang; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2009-03-08       Impact factor: 4.060

Review 7.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

8.  Induction of ERBB2 nuclear transport after radiation in breast cancer cells.

Authors:  Bo Luo; Shiying Yu; Liang Zhuang; Shu Xia; Zhen Zhao; Lei Rong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

9.  Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

Authors:  Jidong Hong; Yuping Peng; Yuping Liao; Wuzhong Jiang; Rui Wei; Lei Huo; Zaide Han; Chaojun Duan; Meizuo Zhong
Journal:  Exp Ther Med       Date:  2012-04-19       Impact factor: 2.447

Review 10.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.